



SERVICES AND PRODUCTS >> Products/SSEER

**SSEER™**

SSEER (Simultaneous Secure Electronic Entry and Reporting) is a breakthrough integrated system for entering, reporting, and analyzing patient data from observational studies in registries and clinical databases. SSEER is ideal for use in post-launch product studies, and is suitable for studies in any therapeutic area.

Among SSEER's advantages:

- Secure centralized data storage
- Real-time access to data and reports from one site or the entire study
- Built-in analytical tools
- Custom reports easily available

Both record entry and data analysis are web-based, supporting single and/or multiple sites. The data is hosted by ProSanos, for both security and database maintenance. As needed, ProSanos can also provide study coordinators, and can facilitate data entry and monitoring functions.

Standard reports include demographics, medical history, diagnosis, and treatment. Custom reports allow user-selectable categories so areas of special interest can be queried.

Security is integrated, role-based, and multi-layered. User roles are limited by password to only specifically authorized areas: data entry, validation/authorization, or site reporting. Electronic case report feature real-time edit checks. The system is HIPAA and 21CFR 11 compliant.

**Benefits for sponsors**

- Sponsors can determine content of interest to be captured for scientific study and analysis (for instance, targeted for publications and scientific abstracts) and possible regulatory submission
- CRF design allows data to be captured on both sponsor and competitor drugs to answer critical questions in the scientific community
- System facilitates disease awareness at sites, and sponsor visibility within the disease-focused community
- Advisory Board and investigators are often disease experts and may be scientific thought leaders

**Benefits for providers**

- Outcomes can be monitored continuously through both standard and customized reporting
- Data is retrieved in real time, and results show both the experience of the user's site and aggregated project-wide reports (after records are de-identified)
- Reimbursement and analytical support are scaled to encourage enrollment


**Benefits for researchers**

- Collaborative research environment includes thought leaders and investigators from many sites
- Data is input on patients receiving sponsor's drug and competitors' products
- Real-time access (after data entry phase) to working sets of data and analysis for investigator's own site, and for all sites combined
- Funding for clinical investigator on site often supplied by sponsor
- Data quality and analytical results suitable for publication
- Low overhead to participate in multi-center trial and outcome experience

**Other products:**

- [PATHTM](#) (Predictive Analytical Tools and Techniques for Healthcare)
- [SSIIFTM](#) (Stratification and Synchronization Inference Technology)

[Return to top](#)



*Investigators have real-time access to demographic reports from their own sites or all sites.*



**SSEER™**

**SSEER facilitates the creation and management of registries and clinical databases that provide results for sponsors, providers, and investigators.**

**SCENARIO:  
Using a Provider's Patient Data in Clinical Trials**

**CHALLENGE** - A pharmaceutical company is interested in conducting Phase IV clinical trials of a cardiovascular drug currently on the market. A large, multi-site health care provider has thousands of cardiac patients under its care; with the right system for gathering, organizing, and analyzing data, those patients could be an invaluable asset for the new trial.

**SOLUTION** - The trial employs ProSanos's unique, web-based SSEER™ (Simultaneous Secure Electronic Entry and Reporting) system. Individualized CRFs—tailored to the sponsor's needs—are developed, and SSEER is quickly operational, allowing convenient, accuracy-checked entry of data and real-time reporting on patients entered into the trial.

**BENEFITS** - Using SSEER, the provider quickly and accurately identifies patient subpopulations meeting the trial's criteria. In addition to helping the pharmaceutical sponsor achieve its objectives in the trial, the client also performs rigorous outcomes analyses on the patient population, helping to enhance the quality and lower the cost of care for its cardiac patients.

[Other Scenarios](#)